ASCO Names Top 6 Ca Advances

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 1
Volume 16
Issue 1

In its second annual "Clinical Cancer Advances" report, the American Society of Clinical Oncology (ASCO) selected six notable developments in clinical cancer research as most important in 2006.

ALEXANDRIA, Virginia—In its second annual "Clinical Cancer Advances" report, the American Society of Clinical Oncology (ASCO) selected six notable developments in clinical cancer research as most important in 2006. ASCO's top six list, which it did not rank in any order, are as follows:

FDA approval of a vaccine (Gardasil) to prevent HPV infection, which is strongly associated with cervical cancer. ASCO called the vaccine "the most significant advance in cancer prevention over the last year."

The first new treatments for renal cancer in more than 20 years. Patients with advanced, high-risk kidney cancer who received first-line treatment with the investigational drug temsirolimus (CCI-779) had improved survival. Patients treated with sunitinib (Sutent) showed improved progression-free survival and response rates.

Lapatinib (Tykerb) improves the treatment of advanced breast cancer. Researchers found that in women whose advanced HER2-positive breast cancer progressed despite trastuzumab (Herceptin) therapy, the addition of lapatinib controlled cancer growth more effectively than chemotherapy alone.

Phase I evidence for the effectiveness of dasatinib (Sprycel) in chronic myelogenous leukemia. Researchers found in the study that 92.5% of CML patients resistant to imatinib (Gleevec) or who cannot tolerate the drug had no evidence of their disease after receiving dasatinib. Following publication of the study, FDA approved Sprycel for CML.

Cetuximab (Erbitux) provides the first new treatment for head and neck cancer in 45 years. A multinational study found that cetuximab added to standard high-dose radiation therapy with locally advanced disease prolonged survival, compared with radiation alone.

Genetic test to predict lung cancer prognosis. Researchers developed a novel gene profiling test, called the lung metagene model, that can predict which patients with early-stage non-small-cell lung cancer (NSCLC) are most likely to be cured and which are most likely to have a recurrence.

In the report, ASCO also urged action in 2007 in two key areas: increased federal funding for cancer research (by a minimum of 5% annually) and greater access to biospecimens.

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content